Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | DDX3X | O00571 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209453 | 0.83 | ALDH1A1 (0.66) | ALDH1A1DDX3XPTGS1SMN1; SMN2HDAC3 | |
| SCHEMBL19675849 | 0.82 | ALDH1A1 (0.64) | ALDH1A1DDX3XPTGS1SMN1; SMN2HDAC3 | |
| SCHEMBL3220116 | 0.82 | ALDH1A1 (0.64) | ALDH1A1DDX3XPTGS1SMN1; SMN2HDAC3 | |
| SCHEMBL2723870 | 0.80 | L3MBTL1 (0.65) | ALDH1A1DDX3XPTGS1SMN1; SMN2HDAC3 | |
| SCHEMBL7956933 | 0.80 | MAPT (0.52) | ALDH1A1PTGS1SMN1; SMN2L3MBTL1PDK1 | |
| SCHEMBL8321463 | 0.80 | PDK1 (0.61) | ALDH1A1SMN1; SMN2HDAC3HDAC4HDAC1 | |
| SCHEMBL16444667 | 0.77 | ALDH1A1 (0.57) | ALDH1A1DDX3XPTGS1SMN1; SMN2HDAC3 | |
| SCHEMBL28021717 | 0.77 | ALDH1A1 (0.57) | ALDH1A1DDX3XPTGS1SMN1; SMN2HDAC3 | |
| SCHEMBL9427642 | 0.77 | DDX3X (0.65) | ALDH1A1DDX3XPTGS1SMN1; SMN2HDAC3 | |
| SCHEMBL11423971 | 0.77 | DDX3X (0.65) | ALDH1A1DDX3XPTGS1SMN1; SMN2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1417186-B1 | HETEROCYCLIC ARYL SULPHONAMIDES | AICURIS GMBH & CO KG (DE) | 2011-03-16 | — | — | EP | disclosed |
| EP-1417186-B1 | HETEROCYCLIC ARYL SULPHONAMIDES | AICURIS GMBH & CO KG (DE) | 2011-03-16 | — | — | EP | disclosed |
| US-7115612-B2 | Arylsulfonamides as antiviral agents | BAYER AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-7115636-B2 | Hetrocyclic aryl sulphonamides | BAYER HEALTHCARE AG (DE) | 2006-10-03 | — | — | US | disclosed |
| EP-1383749-B1 | ARYLSULFONAMIDES AS ANTIVIRAL AGENTS | BAYER HEALTHCARE AG (DE) | 2005-11-02 | — | — | EP | disclosed |
| US-20050085549-A1 | Hetrocyclic aryl sulphonamides | AIC246 AG & CO. KG (DE) | 2005-04-21 | — | — | US | disclosed |
| US-20040176374-A1 | Arylsulfonamides as antiviral agents | AIC246 AG & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| CN-1516695-A | Arylsulfonamides as antiviral agents | — | 2004-07-28 | — | — | CN | disclosed |
| US-20040122076-A1 | Sulphonamides for the treatment of central nervous system diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1417186-A2 | HETEROCYCLIC ARYL SULPHONAMIDES | Bayer HealthCare AG (DE) | 2004-05-12 | — | — | EP | disclosed |
| EP-1383749-A1 | ARYLSULFONAMIDES AS ANTIVIRAL AGENTS | Bayer HealthCare AG (DE) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003014094-A2 | HETEROCYCLIC ARYL SULPHONAMIDES | BAYER HEALTHCARE AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| US-6498183-B1 | TREATMENT AND PROPHYLAXIS OF DISORDERS CAUSED BY HERPES VIRUSES, IN PARTICULAR HUMAN CYTOMEGALOVIRUS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-24 | — | — | US | disclosed |
| WO-2002085869-A1 | ARYLSULFONAMIDES AS ANTIVIRAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122076-A1 | Sulphonamides for the treatment of central nervous system diseases | HTR6, SLC6A4, AANAT | ALDH1A1 1365/4885DDX3X 2318/4885PTGS1 825/4885 |
| US-20050085549-A1 | Hetrocyclic aryl sulphonamides | SULT2A1, STS, SULT1E1 | ALDH1A1 1443/4885DDX3X 98/4885PTGS1 2357/4885 |
| US-20040176374-A1 | Arylsulfonamides as antiviral agents | IFNAR1, ARSA, TPMT | ALDH1A1 1239/4885DDX3X 158/4885PTGS1 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.